Form 4: Supernus Pharmaceuticals CEO Jack A. Khattar Reports Acquisition of Performance Share Units

Sentiment:

SEC Filing


Jack A. Khattar, CEO of Supernus Pharmaceuticals, reports the acquisition of 38,640 Performance Share Units.

Summary

  • On February 19, 2025, Jack A. Khattar, the President and CEO of Supernus Pharmaceuticals, filed a Form 4.
  • The report details the acquisition of 38,640 Performance Share Units on February 17, 2025.
  • These units vest upon achievement of individual performance objectives established on June 24, 2024.
  • Following the reported transaction, Khattar directly owns 953,579 shares of common stock and indirectly owns 1,022,450 shares through the KBT Trust.
  • He also directly owns 38,640 Performance Share Units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Positives

  • The acquisition of Performance Share Units aligns the CEO's interests with the company's performance objectives.

Future Outlook

The vesting of the Performance Share Units is contingent upon the achievement of individual performance objectives within a defined performance period.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

  • The acquisition of Performance Share Units aligns management's interests with those of shareholders.

Key Dates

DateDescription
June 24, 2024Date on which individual performance objectives were established for the Performance Share Units.
February 17, 2025Date of transaction: Acquisition of Performance Share Units.
February 19, 2025Date of filing the Form 4.

Keywords

Form 4, Supernus Pharmaceuticals, Performance Share Units, Jack A. Khattar, Beneficial Ownership, Equity Securities

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.